1. Home
  2. ALVOW
  3. ALVOW News

Latest Alvotech Warrant (ALVOW) News on April 3, 2025

Alvotech (NASDAQ:ALVO) Just Reported And Analysts Have Been Lifting Their Price Targets
ALVOW

Simply Wall St.

4 days ago

Alvotech (NASDAQ:ALVO) Just Reported And Analysts Have Been Lifting Their Price Targets

Alvotech Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
ALVOW

Simply Wall St.

6 days ago

Alvotech Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer
ALVOW

GlobeNewswire

7 days ago

Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer
ALVOW

GlobeNewswire

7 days ago

Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

Alvotech Reports Record Results for 2024 and Provides Business Update
ALVOW

GlobeNewswire

7 days ago

Alvotech Reports Record Results for 2024 and Provides Business Update

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
ALVOW

GlobeNewswire

8 days ago

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
ALVOW

GlobeNewswire

14 days ago

Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
ALVOW

Business Wire

16 days ago

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Exploring 3 High Growth Tech Stocks In The US Market
ALVOW

Simply Wall St.

21 days ago

Exploring 3 High Growth Tech Stocks In The US Market

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida
ALVOW

GlobeNewswire

a month ago

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET
ALVOW

GlobeNewswire

a month ago

Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
ALVOW

GlobeNewswire

a month ago

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
ALVOW

GlobeNewswire

a month ago

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
ALVOW

GlobeNewswire

a month ago

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Pagaya Technologies And 2 Other High Growth Tech Stocks In The US
ALVOW

Simply Wall St.

2 months ago

Pagaya Technologies And 2 Other High Growth Tech Stocks In The US

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
ALVOW

GlobeNewswire

2 months ago

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

Alvotech's (NASDAQ:ALVO) largest shareholders are private equity firms with 34% ownership, private companies own 31%
ALVOW

Simply Wall St.

2 months ago

Alvotech's (NASDAQ:ALVO) largest shareholders are private equity firms with 34% ownership, private companies own 31%

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
ALVOW

GlobeNewswire

3 months ago

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

Exploring Three High Growth Tech Stocks in the United States
ALVOW

Simply Wall St.

4 months ago

Exploring Three High Growth Tech Stocks in the United States

Alvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023)
ALVOW

Simply Wall St.

5 months ago

Alvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023)

ALVOW

GuruFocus.com

5 months ago

Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements

Alvotech Reports Financial Results for the First Nine Months of 2024
ALVOW

GlobeNewswire

5 months ago

Alvotech Reports Financial Results for the First Nine Months of 2024

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
ALVOW

GlobeNewswire

5 months ago

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
ALVOW

GlobeNewswire

5 months ago

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
ALVOW

GlobeNewswire

5 months ago

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET

Exploring High Growth Tech Stocks In The US October 2024
ALVOW

Simply Wall St.

5 months ago

Exploring High Growth Tech Stocks In The US October 2024

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
ALVOW

GlobeNewswire

5 months ago

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
ALVOW

GlobeNewswire

5 months ago

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
ALVOW

GlobeNewswire

5 months ago

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
ALVOW

GlobeNewswire

6 months ago

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

High Growth Tech Stocks in the United States to Watch
ALVOW

Simply Wall St.

6 months ago

High Growth Tech Stocks in the United States to Watch

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®
ALVOW

GlobeNewswire

6 months ago

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
ALVOW

GlobeNewswire

7 months ago

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Alvotech Second Quarter 2024 Earnings: EPS: US$0.25 (vs US$0.83 in 2Q 2023)
ALVOW

Simply Wall St.

7 months ago

Alvotech Second Quarter 2024 Earnings: EPS: US$0.25 (vs US$0.83 in 2Q 2023)

Alvotech's (NASDAQ:ALVO) biggest owners are private equity firms who got richer after stock soared 19% last week
ALVOW

Simply Wall St.

8 months ago

Alvotech's (NASDAQ:ALVO) biggest owners are private equity firms who got richer after stock soared 19% last week

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
ALVOW

GlobeNewswire

8 months ago

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
ALVOW

GlobeNewswire

8 months ago

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET
ALVOW

GlobeNewswire

8 months ago

Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET

STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
ALVOW

GlobeNewswire

8 months ago

STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe

Alvotech Announces Closing of Private Debt Financing
ALVOW

GlobeNewswire

9 months ago

Alvotech Announces Closing of Private Debt Financing

Alvotech Announces Closing of Private Debt Financing
ALVOW

GlobeNewswire

9 months ago

Alvotech Announces Closing of Private Debt Financing

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
ALVOW

GlobeNewswire

9 months ago

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Alvotech Issues New Shares to Holders of Convertible Bonds
ALVOW

GlobeNewswire

9 months ago

Alvotech Issues New Shares to Holders of Convertible Bonds

Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
ALVOW

GlobeNewswire

9 months ago

Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024

Alvotech Receives Conversion Notices for Majority of Convertible Bonds
ALVOW

GlobeNewswire

9 months ago

Alvotech Receives Conversion Notices for Majority of Convertible Bonds

Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
ALVOW

GlobeNewswire

10 months ago

Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe

Alvotech and STADA add to Strategic Alliance through Denosumab Partnership
ALVOW

GlobeNewswire

10 months ago

Alvotech and STADA add to Strategic Alliance through Denosumab Partnership

Alvotech Announces Strategic Refinancing Agreement
ALVOW

GlobeNewswire

10 months ago

Alvotech Announces Strategic Refinancing Agreement

Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
ALVOW

GlobeNewswire

10 months ago

Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024

Brokers Are Upgrading Their Views On Alvotech (NASDAQ:ALVO) With These New Forecasts
ALVOW

Simply Wall St.

10 months ago

Brokers Are Upgrading Their Views On Alvotech (NASDAQ:ALVO) With These New Forecasts

Alvotech First Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)
ALVOW

Simply Wall St.

10 months ago

Alvotech First Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
ALVOW

GlobeNewswire

10 months ago

Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
ALVOW

Business Wire

10 months ago

Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
ALVOW

Business Wire

10 months ago

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

Alvotech S.A. Annual General Meeting to be held June 7, 2024
ALVOW

GlobeNewswire

a year ago

Alvotech S.A. Annual General Meeting to be held June 7, 2024

Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
ALVOW

GlobeNewswire

a year ago

Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)

Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
ALVOW

GlobeNewswire

a year ago

Alvotech Announces Participation at BofA Securities Healthcare Conference 2024

Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
ALVOW

GlobeNewswire

a year ago

Alvotech Announces Participation at BofA Securities Healthcare Conference 2024

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
ALVOW

GlobeNewswire

a year ago

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
ALVOW

GlobeNewswire

a year ago

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
ALVOW

GlobeNewswire

a year ago

Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
ALVOW

GlobeNewswire

a year ago

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
ALVOW

Business Wire

a year ago

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
ALVOW

GlobeNewswire

a year ago

Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024

Alvotech Announces Increase in Number of Own Shares
ALVOW

GlobeNewswire

a year ago

Alvotech Announces Increase in Number of Own Shares

Analysts Expect Breakeven For Alvotech (NASDAQ:ALVO) Before Long
ALVOW

Simply Wall St.

a year ago

Analysts Expect Breakeven For Alvotech (NASDAQ:ALVO) Before Long

Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
ALVOW

GlobeNewswire

a year ago

Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
ALVOW

GlobeNewswire

a year ago

Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET

Alvotech Appoints Interim Chief Quality Officer
ALVOW

GlobeNewswire

a year ago

Alvotech Appoints Interim Chief Quality Officer

Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
ALVOW

GlobeNewswire

a year ago

Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share

Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
ALVOW

GlobeNewswire

a year ago

Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
ALVOW

Business Wire

a year ago

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
ALVOW

GlobeNewswire

a year ago

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
ALVOW

GlobeNewswire

a year ago

Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)

Is Alvotech (NASDAQ:ALVO) Trading At A 48% Discount?
ALVOW

Simply Wall St.

a year ago

Is Alvotech (NASDAQ:ALVO) Trading At A 48% Discount?

ALVOW

Reuters

a year ago

UPDATE 1-Brazil's military reinforces border with Venezuela and Guyana due to Esequibo

Microsoft, Tesla, Netflix, and More: Big Names in the Market Worth Talking About
ALVOW

Motley Fool

a year ago

Microsoft, Tesla, Netflix, and More: Big Names in the Market Worth Talking About

Is There Any Hope for Cassava Sciences Stock?
ALVOW

Motley Fool

a year ago

Is There Any Hope for Cassava Sciences Stock?

Brinker International, Inc. (NYSE:EAT) Q2 2024 Earnings Call Transcript
ALVOW

Insider Monkey

a year ago

Brinker International, Inc. (NYSE:EAT) Q2 2024 Earnings Call Transcript

Idaho Milk Products Celebrates Pranav Vashisht’s Best Paper Award at International Conference
ALVOW

GlobeNewswire

a year ago

Idaho Milk Products Celebrates Pranav Vashisht’s Best Paper Award at International Conference

Ireland celebrates its 'Matron Saint' St. Brigid on the 1500th anniversary of her passing
ALVOW

CNW Group

a year ago

Ireland celebrates its 'Matron Saint' St. Brigid on the 1500th anniversary of her passing

7/2024・Trifork adjusts outlook for 2023 financial results and reports strong performance in Trifork Labs
ALVOW

GlobeNewswire

a year ago

7/2024・Trifork adjusts outlook for 2023 financial results and reports strong performance in Trifork Labs

Google starts a limited test of generative AI tools in Maps
ALVOW

Engadget

a year ago

Google starts a limited test of generative AI tools in Maps

Dave Ramsey: 10 Genius Things To Do With Your Money
ALVOW

GOBankingRates

a year ago

Dave Ramsey: 10 Genius Things To Do With Your Money

Northline Seafoods Streamlines Processes From Catch to Customer With the Help of NorthScope ERP Software
ALVOW

ACCESSWIRE

a year ago

Northline Seafoods Streamlines Processes From Catch to Customer With the Help of NorthScope ERP Software

Traefik Labs Appoints Sudeep Goswami as CEO, Founder Emile Vauge Transitions to Chief Technology Officer
ALVOW

Business Wire

a year ago

Traefik Labs Appoints Sudeep Goswami as CEO, Founder Emile Vauge Transitions to Chief Technology Officer

OKI Group Obtains SBT Certification for Greenhouse Gas Emission Reduction Targets
ALVOW

Business Wire

a year ago

OKI Group Obtains SBT Certification for Greenhouse Gas Emission Reduction Targets

CoStar Group to Report Financial Results for Fourth Quarter and Full Year 2023 on February 20, 2024
ALVOW

Business Wire

a year ago

CoStar Group to Report Financial Results for Fourth Quarter and Full Year 2023 on February 20, 2024

Esker Named in First-Ever Gartner® Magic Quadrant™ for Source-to-Pay Suites
ALVOW

Business Wire

a year ago

Esker Named in First-Ever Gartner® Magic Quadrant™ for Source-to-Pay Suites

Mortgage Rates Tick Down
ALVOW

GlobeNewswire

a year ago

Mortgage Rates Tick Down

Old Dominion Freight Line, Inc. (NASDAQ:ODFL) Q4 2023 Earnings Call Transcript
ALVOW

Insider Monkey

a year ago

Old Dominion Freight Line, Inc. (NASDAQ:ODFL) Q4 2023 Earnings Call Transcript

Media layoffs: Google, Paramount, Disney, and others commit to job cuts in 2024
ALVOW

Yahoo Finance

a year ago

Media layoffs: Google, Paramount, Disney, and others commit to job cuts in 2024

Airspace Link FAA-Approved to Provide B4UFLY Services: Streamlining the Safe Integration of Drones into the National Airspace
ALVOW

PR Newswire

a year ago

Airspace Link FAA-Approved to Provide B4UFLY Services: Streamlining the Safe Integration of Drones into the National Airspace

Chapel Hart Kicks Off Ford Truck Month with "This Girl Likes Fords"
ALVOW

Business Wire

a year ago

Chapel Hart Kicks Off Ford Truck Month with "This Girl Likes Fords"

Novartis AG (NYSE:NVS) Q4 2023 Earnings Call Transcript
ALVOW

Insider Monkey

a year ago

Novartis AG (NYSE:NVS) Q4 2023 Earnings Call Transcript

Can Royal Caribbean Stock Double Again in 2024?
ALVOW

Motley Fool

a year ago

Can Royal Caribbean Stock Double Again in 2024?

The Leaders Group sponsors NAIFA’s national events and NAIFA-Colorado
ALVOW

GlobeNewswire

a year ago

The Leaders Group sponsors NAIFA’s national events and NAIFA-Colorado

GCM Grosvenor to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Investor Conference Call on February 13, 2024
ALVOW

GlobeNewswire

a year ago

GCM Grosvenor to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Investor Conference Call on February 13, 2024

CareMax Announces 1-for-30 Reverse Stock Split
ALVOW

Business Wire

a year ago

CareMax Announces 1-for-30 Reverse Stock Split

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
ALVOW

GlobeNewswire

a year ago

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Share on Social Networks: